MX9302088A - Derivados de alfa-tiocarbonilo y alfa-halocarbonilo, proceso para su preparacion y composicion farmaceutica que los comprende. - Google Patents

Derivados de alfa-tiocarbonilo y alfa-halocarbonilo, proceso para su preparacion y composicion farmaceutica que los comprende.

Info

Publication number
MX9302088A
MX9302088A MX9302088A MX9302088A MX9302088A MX 9302088 A MX9302088 A MX 9302088A MX 9302088 A MX9302088 A MX 9302088A MX 9302088 A MX9302088 A MX 9302088A MX 9302088 A MX9302088 A MX 9302088A
Authority
MX
Mexico
Prior art keywords
group
substituted
compound
formula
alpha
Prior art date
Application number
MX9302088A
Other languages
English (en)
Inventor
David Haigh
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929208016A external-priority patent/GB9208016D0/en
Priority claimed from GB929208451A external-priority patent/GB9208451D0/en
Priority claimed from GB929227047A external-priority patent/GB9227047D0/en
Priority claimed from GB929227046A external-priority patent/GB9227046D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9302088A publication Critical patent/MX9302088A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se describe un compuesto de la fórmula (I): o una forma tautomérica del mismo, y/o una sal farmacéuticamente aceptable del mismo, y/o un solvato farmacéuticamente aceptable del mismo, en donde: A1 representa un grupo heterociclilo aromático sustituido o sin sustituir; A2 representa un anillo de benceno que tiene tres sustituyentes opcionales; A3 representa una porción de la fórmula -(CH2)m-CHR1- en donde R1 representa un átomo de halógeno y una porción de la fórmula S(O)pA4, en donde A4 representa hidrógeno, alquilo sustituido o sin sustituir, arilo, aralquilo, alquilcarbonilo o un grupo heterociclilo aromático y p representa cero o un número entero 1 o 2 y m representa cero o un número entero en el rango desde 1 a 5, o A3 representa una porción de la fórmula -CHCR1-, en donde R1 es como se define anteriormente; R2 representa OR3, en donde R3, representa hidrógeno, alquilo, arilo o aralquilo, o R2 representa -NR4R5,en donde R4 y R5 cada uno representan independientemente hidrógeno o alquilo o R4 y R5 conjuntamente con el átomo de nitrógeno al cual están unidos, forman un anillo heterocíclico; X representa O, S o NR, en donde R representa un átomo de hidrógeno, un grupo alquilo, un grupo asilo, un grupo aralquilo, en donde la porción arilo puede estar sustituida o sin sustituir o un grupo arilo sustituido o sin sustituir; y n representa un número entero en el rango desde 2 a 6; también se describe un procedimiento para la preparación de un compuesto tal, una composición farmacéutica que comprende un compuesto tal y el uso de un compuesto tal y la composición en la medicina.
MX9302088A 1992-04-10 1993-04-12 Derivados de alfa-tiocarbonilo y alfa-halocarbonilo, proceso para su preparacion y composicion farmaceutica que los comprende. MX9302088A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929208016A GB9208016D0 (en) 1992-04-10 1992-04-10 Novel compounds
GB929208451A GB9208451D0 (en) 1992-04-16 1992-04-16 Novel compounds
GB929227047A GB9227047D0 (en) 1992-12-29 1992-12-29 Novel compounds
GB929227046A GB9227046D0 (en) 1992-12-29 1992-12-29 Novel compounds

Publications (1)

Publication Number Publication Date
MX9302088A true MX9302088A (es) 1994-07-29

Family

ID=27450858

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302088A MX9302088A (es) 1992-04-10 1993-04-12 Derivados de alfa-tiocarbonilo y alfa-halocarbonilo, proceso para su preparacion y composicion farmaceutica que los comprende.

Country Status (5)

Country Link
EP (1) EP0635007A1 (es)
JP (1) JPH07505647A (es)
AU (1) AU3959193A (es)
MX (1) MX9302088A (es)
WO (1) WO1993021166A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
EP0948327B1 (en) * 1996-12-23 2006-03-08 Merck & Co., Inc. Antidiabetic agents
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
TR199903096T2 (xx) 1997-06-18 2000-08-21 Smithkline Beecham P.L.C. Diabetin tiazolidinedion ve s�lfonil�re ile tedavisi.
DZ2937A1 (fr) 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
SI1131070T1 (sl) 1998-11-12 2008-12-31 Smithkline Beecham Plc Farmacevtski sestavek za modificirano sproĺ äśanje senzibilizatorja za inzulin in metformina
PT1206457E (pt) * 1999-08-27 2004-03-31 Lilly Co Eli Derivados de diaril-oxa(tia)zol e seu uso como moduladores dos ppars
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6784199B2 (en) 2000-09-21 2004-08-31 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
US6768008B2 (en) * 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
AU2001269821A1 (en) 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
EP1698624B1 (en) * 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
PL372332A1 (pl) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
US20100274022A1 (en) * 2007-04-26 2010-10-28 Pharmafrontier Co., Ltd. G protein-coupled receptor inhibitor and pharmaceutical product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
EP0635007A1 (en) 1995-01-25
WO1993021166A1 (en) 1993-10-28
AU3959193A (en) 1993-11-18
JPH07505647A (ja) 1995-06-22

Similar Documents

Publication Publication Date Title
MX9302088A (es) Derivados de alfa-tiocarbonilo y alfa-halocarbonilo, proceso para su preparacion y composicion farmaceutica que los comprende.
MX9303981A (es) Nuevos compuestos farmaceuticos, proceso para su preparacion y composicion farmaceutica que los contiene.
ES2133410T3 (es) Derivados sustituidos de la tiazolidindiona.
PT88410A (pt) Process for preparing thiazolidinedione derivatives
ATE102193T1 (de) Thiazolidinedionederivate.
EP0356214A3 (en) Thiazolidine dione derivatives
DE69016899D1 (de) Thiazolidinedionederivate.
MX9302957A (es) Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ATE34976T1 (de) Arylcyclobutylalkylamine und ihre verwendung als antidepressive arzneimittel.
GB1129072A (en) Benzofuran and indole derivatives
KR880012594A (ko) 벤조- 및 티에노-3,4-디하이드로-피리딘유도체, 이의 제조방법 및 이들 화합물을 함유하는 약제학적 조성물
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
ES426427A1 (es) Un procedimiento para la preparacion de nuevos derivados denitrocarboestirilo.
SE7714685L (sv) Forfarande for framstellning av nya basiskt substituerade o-propyloximer samt deras anvendning sasom lekemedel
GB1192140A (en) New Indane-Diones and their Preparation